Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hematology

Protecting Your Future: Long-Term Monitoring and Cancer Surveillance

At a Glance

Dyskeratosis congenita requires lifelong, individualized monitoring even after a bone marrow transplant because the transplant does not repair the underlying telomere defect in other organs. Regular cancer screening, organ tests, sun protection, and surgical planning help detect problems early.

Because Dyskeratosis Congenita (DC) is a lifelong condition affecting telomere maintenance and chromosome-end protection, ongoing monitoring is the most critical part of your long-term care [1]. A common misconception is that a bone marrow transplant “cures” DC; however, while a transplant replaces the blood system, it does not repair the telomere defect in other organs [1][2]. In fact, the risk of certain cancers can even increase after a transplant due to medications and graft-versus-host disease, making consistent surveillance vital [3][4].

Vigilant Cancer Surveillance

Patients with DC face a high risk of developing certain cancers—particularly squamous cell carcinomas (SCC) of the head, neck, and anogenital regions—at rates far higher than the general population, especially within inherited marrow-failure cohorts [4]. These cancers often appear at a much younger age than usual [4].

  • Oral and Head/Neck: You should have a thorough oral exam by a specialist (like an ENT or specialized dentist) every 6 to 12 months [5]. Any persistent new white patch, ulcer, lump, or bleeding area should prompt an assessment; the specialist will decide if a biopsy is needed [6][7].
  • Anogenital Area: Regular screenings for squamous cell cancers of the cervix, vagina, anus, or penis are essential. These screenings should be tailored to your age and symptoms. Discuss the HPV vaccine with your doctor, as it may provide important protection [4][8].
  • Skin: Regular full-body skin exams by a dermatologist are recommended [9]. Because your cells are highly sensitive to damage, rigorous photoprotection is mandatory: wear wide-brimmed hats, UV-protective clothing, and seek shade [10][11]. Avoid smoking/vaping and moderate alcohol intake to further reduce cancer risks.

Example Organ Monitoring Schedule

Early detection of lung and liver issues allows for earlier intervention. Note that the schedule below contains examples; your actual surveillance plan depends on your age, genotype, symptoms, and transplant history. Furthermore, routine CBCs and bone marrow monitoring for clonal evolution or MDS/AML are a central, frequent part of follow-up not listed here.

System Test Type Frequency (Example) What We Look For
Lungs Pulmonary Function Tests (PFTs) Annually [5] Functional changes like drops in DLCO (how well oxygen moves into the blood) [12][13].
Liver Ultrasound / Elastography Every 1–2 years [14] Signs of scarring or portal hypertension. (Note: Elastography alone does not definitively exclude portal hypertension) [15][16].
Eyes Ophthalmology Exam Indication-based [17] Retinal changes or limbal stem cell deficiency, which affects how the eye heals [17].

Surgical and Imaging Precautions

The telomere defect means your tissues may not heal as well as others.

  • Avoid Elective Eye Surgery: Procedures like LASIK should be avoided, as they can lead to severe healing complications and vision issues [17].
  • General Surgery: Any surgery should be carefully coordinated. Your surgical team must evaluate your marrow reserve, bleeding/infection risks, and lung/liver function before proceeding [18][19].
  • Diagnostic Imaging: Discuss whether an MRI or ultrasound is a viable alternative to minimize radiation exposure. However, do not delay or refuse clinically necessary X-rays or CT scans if your doctor deems them essential for diagnosis.

Managing “Scanxiety”

Living with a schedule of constant medical tests can create a significant emotional burden often called scanxiety. It is normal to feel distress in the weeks leading up to appointments [20].

  • Build a Routine: Having a set plan for your scan days can help create a sense of control.
  • Psychosocial Support: Don’t hesitate to ask for a referral to a psychologist, social worker, or child-life specialist to help process the stress of living with a chronic condition [20][21].

Common questions in this guide

Does a bone marrow transplant cure dyskeratosis congenita?
No. A bone marrow transplant replaces the blood-forming system, but it does not repair the telomere defect in other organs. People still need lifelong monitoring and cancer surveillance after transplant.
What cancer screenings are important for people with dyskeratosis congenita?
Follow-up commonly includes an oral and head-and-neck exam every 6 to 12 months, regular anogenital cancer screening tailored to age and symptoms, and full-body skin exams. The care team may adjust timing based on genotype, symptoms, and transplant history. Ask whether HPV vaccination is appropriate.
What changes should I report between cancer screening visits?
Tell a clinician about a persistent white patch, ulcer, lump, or bleeding area in the mouth, as well as new or changing skin or genital findings. New breathing changes also deserve prompt medical attention. A specialist can decide whether an examination or biopsy is needed.
How often should people with DC have lung and liver monitoring?
Example schedules include pulmonary function tests once a year and liver ultrasound or elastography every one to two years. These are not universal rules; age, genotype, symptoms, and transplant history affect the plan. Blood counts and bone marrow monitoring are also frequent parts of follow-up.
Should I avoid CT scans or X-rays if I have dyskeratosis congenita?
Do not delay or refuse an X-ray or CT scan that your doctor considers necessary. When clinically appropriate, ask whether MRI or ultrasound could answer the question without radiation exposure. The best choice depends on the medical problem and should be decided with your care team.
Can I have LASIK or other elective surgery with dyskeratosis congenita?
Elective eye surgery such as LASIK is generally avoided because abnormal tissue healing can cause serious complications and vision problems. Any other surgery should be planned with assessment of blood counts, bleeding and infection risks, and lung and liver function. Discuss dental work and other elective procedures with your medical team before scheduling them.
How can I cope with scanxiety from ongoing monitoring?
Scanxiety, or distress before medical tests, is common in people living with a chronic condition. A consistent routine on scan days and support from a psychologist, social worker, or child-life specialist may help. Ask your team for a referral if worry is interfering with daily life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific specialists (dermatology, ENT, gynecology/urology) should I see for my cancer screenings, and how do they coordinate with my hematologist?
  2. 2.Since I have had a bone marrow transplant, how does my risk for squamous cell carcinoma change, and should we increase the frequency of my exams?
  3. 3.What are the current 'baseline' values for my pulmonary function tests (PFTs) and liver elastography, and what changes would be cause for concern?
  4. 4.If I need diagnostic imaging, can we discuss whether MRI or ultrasound is a viable alternative to minimize radiation exposure without delaying needed care?
  5. 5.Can we review the risks of any elective procedures I am considering, such as dental work or vision correction, in the context of my diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.

    Fioredda F, Iacobelli S, Korthof ET, et al.

    British journal of haematology 2018; (183(1)):110-118 doi:10.1111/bjh.15495.

    PMID: 29984823
  2. 2

    Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?

    Hudda Z, Myers KC

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):141-148 doi:10.1182/hematology.2023000471.

    PMID: 38066882
  3. 3

    Genotype and Associated Cancer Risk in Individuals With Telomere Biology Disorders.

    Niewisch MR, Kim J, Giri N, et al.

    JAMA network open 2024; (7(12)):e2450111 doi:10.1001/jamanetworkopen.2024.50111.

    PMID: 39661387
  4. 4

    Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up.

    Alter BP, Giri N, Savage SA, Rosenberg PS

    Haematologica 2018; (103(1)):30-39 doi:10.3324/haematol.2017.178111.

    PMID: 29051281
  5. 5

    Stem cell transplantation and gene therapy for telomere biology disorders: Historical perspective, current approaches, and emerging strategies.

    Koo J, Reed HD, Myers KC, Agarwal S

    Seminars in hematology 2025; (62(6)):493-502 doi:10.1053/j.seminhematol.2026.03.001.

    PMID: 41916788
  6. 6

    Malignant transformation of oral leukoplakia in a patient with dyskeratosis congenita.

    Bongiorno M, Rivard S, Hammer D, Kentosh J

    Oral surgery, oral medicine, oral pathology and oral radiology 2017; (124(4)):e239-e242 doi:10.1016/j.oooo.2017.08.001.

    PMID: 28923296
  7. 7

    An update on the biology and management of dyskeratosis congenita and related telomere biology disorders.

    Niewisch MR, Savage SA

    Expert review of hematology 2019; (12(12)):1037-1052 doi:10.1080/17474086.2019.1662720.

    PMID: 31478401
  8. 8

    Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia.

    Chihanga T, Vicente-Muñoz S, Ruiz-Torres S, et al.

    Cancers 2022; (14(8)) doi:10.3390/cancers14082040.

    PMID: 35454946
  9. 9

    Two Cases of Dyskeratosis Congenita with Clinically Distinct Presentations, Seen in National University Hospital, Singapore.

    Juay L, Chandran NS

    Skin appendage disorders 2022; (8(1)):53-56 doi:10.1159/000518299.

    PMID: 35111818
  10. 10

    Photoprotection in specific populations: Children and people of color.

    Cestari T, Buster K

    Journal of the American Academy of Dermatology 2017; (76(3S1)):S110-S121 doi:10.1016/j.jaad.2016.09.039.

    PMID: 28038884
  11. 11

    What's New in Photoprotection?

    Álvarez-Bobillo Z, Gracia-Cazaña T, Gilaberte Y, Lim HW

    American journal of clinical dermatology 2026; (27(4)):683-695 doi:10.1007/s40257-026-01047-w.

    PMID: 42260063
  12. 12

    Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder.

    Giri N, Ravichandran S, Wang Y, et al.

    ERJ open research 2019; (5(4)) doi:10.1183/23120541.00209-2019.

    PMID: 31754622
  13. 13

    Diagnosis and management of telomere biology disorders in developing countries.

    Rodríguez A, Avendaño-Robles BA, Catto MB, et al.

    Seminars in hematology 2025; (62(6)):521-531 doi:10.1053/j.seminhematol.2026.04.004.

    PMID: 42177138
  14. 14

    Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders.

    Vittal A, Niewisch MR, Bhala S, et al.

    Hepatology (Baltimore, Md.) 2023; (78(6)):1777-1787 doi:10.1097/HEP.0000000000000461.

    PMID: 37184208
  15. 15

    Liver-associated findings and outcomes in a telomere biology disorders clinic.

    Nguyen KM, Ongie L, Xu P, et al.

    Hepatology communications 2026; (10(9)) doi:10.1097/HC9.0000000000001021.

    PMID: 42612102
  16. 16

    Transient elastography in adult patients with cryptic dyskeratosis congenita reveals subclinical liver fibrosis: a retrospective analysis of the Aachen telomere biology disease registry.

    Tometten M, Kirschner M, Isfort S, et al.

    Orphanet journal of rare diseases 2021; (16(1)):395 doi:10.1186/s13023-021-02024-8.

    PMID: 34565437
  17. 17

    Dyskeratosis Congenita and Corneal Refractive Surgery.

    Heiland MB, Moshirfar M, Rosen DB, et al.

    Ophthalmology and therapy 2019; (8(3)):361-365 doi:10.1007/s40123-019-0200-z.

    PMID: 31313220
  18. 18

    Dyskeratosis Congenita: A Case Report of a Patient With Coronary Artery Disease.

    Ghaly M, Ghaly M, Harris S

    Cureus 2023; (15(6)):e40939 doi:10.7759/cureus.40939.

    PMID: 37496551
  19. 19

    Dyskeratosis congenita and squamous cell carcinoma of the mandibular alveolar ridge.

    Manfuso A, Risitano AM, Copelli C

    BMJ case reports 2021; (14(5)) doi:10.1136/bcr-2021-242459.

    PMID: 33975847
  20. 20

    Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature.

    Tsoi A, Gomez A, Boström C, et al.

    Rheumatology international 2024; (44(5)):765-778 doi:10.1007/s00296-024-05548-x.

    PMID: 38451302
  21. 21

    The effect of 'I am Protecting my Child from the Sun' programme on parental sun protection behaviours: Randomized controlled trial.

    Sümen A, Öncel S

    Journal of advanced nursing 2021; (77(1)):387-400 doi:10.1111/jan.14614.

    PMID: 33089943

This page explains long-term monitoring and cancer surveillance for dyskeratosis congenita for educational purposes only and does not replace medical advice. Work with your hematology and specialty teams to create a plan tailored to your age, genotype, symptoms, and transplant history.

Get notified when new evidence is published on Dyskeratosis congenita.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.